Cognitive impairment in pulmonary arterial hypertension.

Pulmonary arterial hypertension (PAH) is characterized by progressive pulmonary vascular remodeling with resultant abnormal increase in pulmonary artery pressure and right heart dysfunction. There is evidence that PAH includes cognitive impairment. However, the cognitive impairment syndrome has not been well described, and both the underlying mechanism and the relationship between cardiopulmonary and cognitive dysfunction in PAH are unknown. We performed cognitive evaluations and same day sub-maximum cardiopulmonary exercise testing on adult subjects with PAH. A frontal-subcortical syndrome suggestive of vascular cognitive impairment was found in 26% of subjects and was associated with noninvasive markers of pulmonary vascular remodeling.

Carotid Stenosis and Impaired Cognition: The Effect of Intervention.

There is a clear association between carotid artery stenosis and cognitive impairment. However, there is no consensus as to how to interpret this association, and what, if any, impact this connection should have on the management of carotid stenosis. A review of the relevant literature suggests that although an intervention to relieve carotid stenosis in patients without clinically significant cognitive impairment does not improve cognition, there may be a cognitive benefit with intervention for carotid stenosis in those patients with clinically significant cognitive disorders.

Comprehensive, Individualized, Person-Centered Management of Community-Residing Persons with Moderate-to-Severe Alzheimer Disease: A Randomized Controlled Trial.

BACKGROUND/AIMS: The aim was to examine added benefits of a Comprehensive, Individualized, Person-Centered Management (CI-PCM) program to memantine treatment. METHODS: This was a 28-week, clinician-blinded, randomized, controlled, parallel-group study, with a similar study population, similar eligibility criteria, and a similar design to the memantine pivotal trial of Reisberg et al. [N Engl J Med 2003;348:1333-1341]. Twenty eligible community-residing Alzheimer disease (AD) subject-caregiver dyads were randomized to the CI-PCM program (n = 10) or to usual community care (n = 10). Primary outcomes were the New York University Clinician's Interview-Based Impression of Change Plus Caregiver Input (NYU-CIBIC-Plus), assessed by one clinician set, and an activities of daily living inventory, assessed by a separate clinician set at baseline and at weeks 4, 12, and 28. RESULTS: Primary outcomes showed significant benefits of the CI-PCM program at all post-baseline evaluations. Improvement on the NYU-CIBIC-Plus in the management group at 28 weeks was 2.9 points over the comparator group. The memantine 2003 trial showed an improvement of 0.3 points on this global measure in memantine-treated versus placebo-randomized subjects at 28 weeks. Hence, globally, the management program intervention benefits were 967% greater than memantine treatment alone. CONCLUSION: These results are approximately 10 times those usually observed with both nonpharmacological and pharmacological treatments and indicate substantial benefits with the management program for advanced AD persons.

Validation of the English Version of the Multimodal Assessment of Capacities in Severe Dementia (MAC-SD): A Cognitive and Functional Scale for Use in Severe Dementia.

BACKGROUND: Most existing screening instruments that assess cognition and functioning in dementia suffer from floor effects, limiting their utility in severely demented patients. In 2015, the first author devised a new instrument, The Multimodal Assessment of Capacities in Severe Dementia (MAC-SD), to address this need. The MAC-SD Spanish version proved reliable, valid, and useful for evaluating patients with severe dementia. OBJECTIVE: This report presents the results of a field trial of the English version of the MAC-SD in a U.S. population. METHODS: The MAC-SD was administered to 40 participants with severe dementia along with gold standard measures of cognition and functioning in dementia (the Severe Mini-Mental State Exam, the Severe Impairment Battery, the Global Deterioration Scale, and the Barthel Index of Activities of Daily Living). Data analysis was performed to determine floor effects, reliability, validity, sensitivity to change, and clinical usefulness. RESULTS: The MAC-SD showed no significant floor effects, acceptable reliability, convergent validity with control measures, internal validity, and known groups validity. Of participants who scored the lowest possible on control measures, MAC-SD scores ranged widely. The MAC-SD was highly sensitive to change, and was able to detect changes not seen on control measures. CONCLUSIONS: The MAC-SD English version is reliable and valid for use in the cognitive and functional assessment of patients with severe dementia. It gives more detailed information than control instruments about the cognitive and functional abilities of patients with the most severe dementia, and is able to detect changes in these patients not shown by control measures.

Validation of the multimodal assessment of capacities in severe dementia: a novel cognitive and functional scale for use in severe dementia.

The multimodal assessment of capacities in severe dementia (MAC-SD), a novel cognitive and functional assessment, was developed for use with patients with severe dementia. Its psychometric attributes were examined in a unicenter, open, observational study. The MAC-SD along with the Spanish language Severe Mini Mental Exam were administered to 103 patients with a diagnosis of severe dementia. Psychometric analyses were performed to determine acceptability, reliability, validity, and responsiveness. As a whole, the MAC-SD sections showed no floor effects, satisfactory internal consistency, reproducibility, construct validity, precision, and sensitivity to change. The MAC-SD performed as a useful, valid, and potentially responsive tool to measure cognition and functioning in the most advanced stages of dementia.